Drug development capacity building between UCR and City of Hope to speed cancer therapies
Official title: 2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership
Funded at University of California Riverside · NIH-11411303 · Data updated 2026-11-12
A UCR-CoH partnership aims to strengthen drug development and training so that local ideas can move toward cancer therapies and clinical trials.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,112,848 |
| NIH project number | 5U54CA285114-04 |
| Project ID | NIH-11411303 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with breast cancer or hematologic cancers seen at participating institutions may benefit indirectly through accelerated therapy development and access to future trials.
✕Less likely to help
Patients not enrolled in future trials or those outside the participating institutions may not directly benefit.
What this research studies
This grant supports a collaboration between the University of California, Riverside and City of Hope Comprehensive Cancer Center to build resources, infrastructure, and training for drug development. It focuses on expanding the pipeline from discovery to clinic, including mentorship for cancer biologists, drug development scientists, and clinical trialists. The effort leverages prior success to foster joint research projects, fellowships, and translational programs that could lead to new therapies for cancers such as breast cancer and leukemia. By enhancing capacity and collaboration, patients could benefit from faster access to new treatment options in the future.
Why it matters
Potential benefit: It could speed the development of new cancer therapies and provide more training pathways that lead to future clinical trials for patients.
How similar studies have gone: Prior collaborations have yielded joint grants and early-stage translational work, showing progress in building drug development capacity.
Where this research is happening
-
University of California Riverside
Riverside, United States Active
Researchers
- Principal investigator: Martinez, Ernest — University of California Riverside
- Study coordinator: Martinez, Ernest
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.